Given a passage with a question and an answer to that question, classify if the answer actually answers the question into 'yes' or 'no'. Output 'yes' if the answer answers the question and output 'no' if the answer does not answer the question.

Q: Question: Does the presence of high-grade prostatic intraepithelial neoplasia or atypia on prostate biopsy adversely affect prostatectomy outcomes for patients otherwise eligible for active surveillance?
Answer: The presence of HGPIN or ASAP does not increase the risk of upgrading, upstaging, or adverse pathology at the time of prostatectomy for patients who meet the AS criteria. If otherwise suitable, HGPIN and ASAP should not impact the decision to choose AS. However, analysis of prospective AS trials is required to determine if HGPIN or ASAP impacts tumor progression once on AS.

A: no
****
Q: Question: Does apelin-13 protect the heart against ischemia-reperfusion injury through the RISK-GSK-3β-mPTP pathway?
Answer: The protective mechanism of apelin-13 might be that inactivation of GSK-3β could inhibit the opening of mPTP by activating PI3K/Akt and ERK1/2 involved in the reperfusion injury salvage kinase (RISK) pathway.

A: yes
****
Q: Question: Does isotretinoin prolong QT intervals and QT dispersion in patients with severe acne : a surprising finding for a drug with numerous side effects?
Answer: In patients with severe acne, six months of 0.8 mg/kg/day of isotretinoin therapy neither prolongs QT interval, nor increases QT dispersion. This effect is not related to blood lipids, homocysteine or lipoprotein (a) levels. Our findings indicate that from the point of polymorphic ventricular tachycardia risk, 0.8 mg/kg/day of isotretinoin therapy is a safe choice in acne treatment.

A:
no
****